Metastatic HR+ Breast Cancer: Year in Review

Expert oncologists share their perspectives on key updates in the management of hormone receptor–positive metastatic breast cancer from the past year.

EP. 1: HR+ Metastatic Breast Cancer: Overview of the Current Treatment Landscape

October 4th 2022

Opening their discussion on the HR+ metastatic breast cancer treatment landscape, expert oncologists share a broad overview of treatment modalities in this setting.

EP. 2: What is the Role of Oral SERD Therapy in HR+ Metastatic Breast Cancer?

October 4th 2022

Comprehensive insight to the development and use of selective estrogen receptor degraders [SERDs] in HR+ metastatic breast cancer treatment.

EP. 3: Brief Review of SERM Therapy Data in HR+ Metastatic Breast Cancer

October 11th 2022

Closing out their review of endocrine therapy in HR+ metastatic breast cancer, panelists consider clinical trial data with selective estrogen receptor modulators [SERMs].

EP. 4: Interpreting Data With CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

October 11th 2022

In the context of recent clinical trials, experts share their perspective on the selection and use of CKD4/6 inhibitor therapy in patients with HR+ metastatic breast cancer.

EP. 5: HR+ Metastatic Breast Cancer: Continuing CDK4/6 Inhibition Beyond Progression

October 18th 2022

Expert panelists consider when it is appropriate to continue the use of CDK4/6 inhibitors beyond progression in HR+ metastatic breast cancer.

EP. 6: Treatment for HR+ Metastatic Breast Cancer After Progression on CDK4/6 Inhibitors

October 18th 2022

Shared insight on appropriate treatment options for patients with HR+ metastatic breast cancer following progression on CDK4/6 inhibitors.

EP. 7: HER2-Low Metastatic Breast Cancer and Use of Trastuzumab Deruxtecan

October 25th 2022

Centering their discussion on the HER2 low setting of HR+ metastatic breast cancer, medical oncologists review data behind trastuzumab deruxtecan therapy.

EP. 8: HR+ Metastatic Breast Cancer: What is the Role of Antibody-Drug Conjugates?

October 25th 2022

Centering discussion on antibody-drug conjugates in HR+ metastatic breast cancer, panelists consider the selection and use of these agents in practice.

EP. 9: Ongoing Clinical Trials With ADC Therapy in HR+ Metastatic Breast Cancer

November 1st 2022

Breast medical oncologists close out the program on HR+ metastatic breast cancer by highlighting ongoing clinical trials with antibody-drug conjugate therapy.